- Biocon Q1 Results: Profit rises 71% YoY to Rs 144 crore
Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1 ...More
Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1FY23, while the generic business rose 19% to Rs 580 crore.Biocon said that its net profit and margins would have been much higher, had it not been for higher R&D and other expenses. ...Less
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%
The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 3 ...More
The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily related to the biosimilar business acquisition cost. ...Less
- Biocon Q1 profit surges 72% to Rs 206 crore
Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration. ...More
Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration. ...Less
- Biocon shares in focus after Q3 PAT drops 96% YoY, 1.5% additional stake acquisition in subsidiary
Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 c ...More
Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...Less
- What changed your markets while you were sleeping
Asian stocks inched higher on Friday, buoyed by gains in U.S. technology shares. ...More
Asian stocks inched higher on Friday, buoyed by gains in U.S. technology shares. ...Less
- Biocon plans $150-million capex in two years
Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancin ...More
Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future growth, with analysts maintaining a positive outlook. ...Less
- Nifty22,808.5095.41Sensex73,582.53262.98
- Trent3,785.00234.41
- USD/INR92.85-0.26
Load More
Biocon Q1 Earnings
Open in App